Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Updated Results from the Phase 2 Waveline-004 Study of Zilovertamab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Lalita Norasetthada, Joaquin Diaz, Fangfang Lv, Yuqin Song, Seung Tae Lee, Ewa Paszkiewicz-Kozik, Dipenkumar Modi, Armando Santoro, Kumudu Pathiraja, Nishitha Reddy, Rushdia Yusuf, Muhit Ozcan

Blood (2024) 144 (Supplement 1): 1738.

https://doi.org/10.1182/blood-2024-201522

Published: 2024

Journal Articles

Epidemiology, Clinical Features and Outcomes of Peripheral T-Cell Lymphoma in Latin America

Thais Fischer, Henry Idrobo, Astrid Pavlovsky, Denisse Castro, Brady Beltran, Daniel J Enriquez, Jule F Vasquez, Claudia Roche, Daniel Artiles, Fabiola Valvert, Luis Mario Villela, Juliana Pereira, Carolina Oliver, Jamila Vaz Tavarez, Sergio Augusto B Brasil, Karin Z Cecyn, Nelson Castro, Renata Baptista, Samuel de S Medina, Davimar Miranda Maciel Borducchi, Marcelo Bellesso, Danielle Leao Cordeiro De Farias, Yung Bruno Gonzaga, Fernando Warley, Lorena Fiad, Laura Korin, Patricio Hernan Pereyra, Camila Peña, Maria Alejandra Torres, Carolina Valeria Mahuad, Alana Von Glasenapp, Alfredo Reinaldo Quiroz, Raimundo Gazitua, Cesar Augusto Samanez-Figari, Lautaro Sardu, Juan Pablo Arriola, Sebastian Isnardi, Juan L. Maradei, Raul Hector Gabus, Alicia I. Enrico, Luciana A Guanchiale, Florencia Negri Arangueren, Juan Ignacio García Altuve, Amalia Cerutti, Romina Penalva, Jose Ignacio Garcia Trucco, Florencia Pessolani, Virginia Gilli, Joaquin Diaz, Maria Enriqueta Martinez, Gustavo Jarchum, Gabriela Celia Perinotto, Teresa Barraza, Sergio Ciarlo, Christine Rojas, Rosa Oliday Rios Jiménez, Carmino De Souza, Martina Manni, Eliana C M CM Miranda, Massimo Federico, Bryan Valcarcel, Carlos Chiattone, Luis Enrique Malpica Castillo

Blood (2023) 142 (Supplement 1): 186.

https://doi.org/10.1182/blood-2023-187254

Published: 2023

Journal Articles

Quantitative Ki-67 Proliferative Index Assessment of Human B-Cell Lymphomas By Flow Cytometry

Felipe Castillo, Constanza Morales, Mirentxu Iruretagoyena, Joaquin Díaz Schmidt, Daniel Ernst

Blood (2023) 142 (Supplement 1): 6131.

https://doi.org/10.1182/blood-2023-190504

Published: 2023

Journal Articles

Zilovertamab Vedotin (MK-2140) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from the Phase 2 Waveline-004 Study

Muhit Ozcan, Fangfang Lv, Lalita Norasetthada, Ewa Paszkiewicz-Kozik, Joaquin Díaz Schmidt, Dipenkumar Modi, Alexander Fosså, Sagun Goyal, Won Seog Kim, Seung Tae Lee, Armando Santoro, Mehmet Sonmez, Kumudu Pathiraja, Nishitha Reddy, Patricia Marinello, Yuqin Song

Blood (2023) 142 (Supplement 1): 1720.

https://doi.org/10.1182/blood-2023-186788

Published: 2023

Journal Articles

Primary CNS Lymphoma in Latin America: A Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL) Survey in 80 Cancer Centers in Latin America

Blood (2023) 142 (Supplement 1): 2422.

https://doi.org/10.1182/blood-2023-190477

Published: 2023

Journal Articles

Increased Frequency of Low-Grade Follicular Lymphoma with a High Proliferative Index: A First Step Towards Histological Transformation? a Retrospective Analysis of 25 Follicular Lymphoma Cases

Joaquin Díaz Schmidt, Nicolás Triantafilo, Biserka Spralja, Daniel Ernst

Blood (2023) 142 (Supplement 1): 6127.

https://doi.org/10.1182/blood-2023-191161

Published: 2023

Journal Articles

Real-World Experience of Venetoclax Combination Therapy in Patients with Acute Myeloid Leukemia (AML): A Single-Institution Retrospective Study in a Middle-Income Country

Natalia Aránguiz, Ximena Valladares, Javiera Donoso, Sebastian Ignacio Ewoldt, Daniel Ernst, Joaquin Diaz, Matias Sanchez

Blood (2022) 140 (Supplement 1): 11723–11724.

https://doi.org/10.1182/blood-2022-164899

Published: 2022

Journal Articles

Kinetics of Response to Bortezomib/Thalidomide/Dexamethasone (VTD) in Multiple Myeloma: Implications for the Choice and Design of Pretransplantation Induction Regimens

Blood (2014) 124 (21): 2108.

https://doi.org/10.1182/blood.V124.21.2108.2108

Published: 2014

Journal Articles

Tumor and Renal Response in Patients with Newly Diagnosed Multiple Mieloma and Renal Failure Treated with Bortezomib and Dexamethasone: Results of a Prospective Phase II Trial from Pethema/GEM

Laura Rosiñol, MD PhD, Albert Oriol, MD, M Jesús Blanchard, Luis Palomera, Maria-Victoria Mateos, Javier De La Rubia, Miguel T Hernandez, MD, Joaquín Díaz-Mediavilla, Jose Mariano Hernandez, Raquel Jiménez, MD, Cristina Motllo, Juan José Lahuerta, MD PhD, Jesus F. San Miguel, Joan Blade

Blood (2014) 124 (21): 4776.

https://doi.org/10.1182/blood.V124.21.4776.4776

Published: 2014

Journal Articles

Observational Prospective Registry for the Assessment of the Clinical Impact of Starting Anti-Myeloma Treatment at Biological Relapse

Adrian Alegre, Merche Gironella, Juan Miguel Bergua, Esther Gonzalez, Fernando Escalante, Alfon Soler, Antonia Sampol, Ana Pilar Gonzalez, Valentin Cabañas, Juan Jose Lahuerta, Aurelio Lopez, Ana Dios, Abelardo Bárez, Antonio Ruiz, David Vilanova, Joaquín Díaz-Mediavilla

Blood (2014) 124 (21): 4765.

https://doi.org/10.1182/blood.V124.21.4765.4765

Published: 2014

Journal Articles

Persistent Benefit of VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Long-Term Follow-up of a Randomized Phase 3 Pethema/GEM Study

Blood (2014) 124 (21): 3457.

https://doi.org/10.1182/blood.V124.21.3457.3457

Published: 2014

Journal Articles

Intensive (2+5) Or Semi-Intensive (FLUGA) Chemotherapy For Patients With Acute Myeloid Leukemia Who Are 70 Years Of Age Or Older

Blood (2013) 122 (21): 2687.

https://doi.org/10.1182/blood.V122.21.2687.2687

Published: 2013

Journal Articles

Minimal Residual Diease Evaluation By Flow Cytometry Is a Complementary Tool To Cytogenetics For Treatment Decision In Acute Myeloid Leukemia

Blood (2013) 122 (21): 2576.

https://doi.org/10.1182/blood.V122.21.2576.2576

Published: 2013

Journal Articles

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

Blood (2012) 120 (8): 1589–1596.

https://doi.org/10.1182/blood-2012-02-408922

Published: 2012

Includes: Supplemental data

Journal Articles

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

Blood (2012) 119 (3): 687–691.

https://doi.org/10.1182/blood-2011-07-370460

Published: 2012

Includes: Supplemental data

Journal Articles

Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance

Blood (2011) 118 (17): 4547–4553.

https://doi.org/10.1182/blood-2011-04-345801

Published: 2011

Journal Articles

Risk-adapted treatment of acute promyelocytic leukemia based on all- trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome

Blood (2010) 115 (25): 5137–5146.

https://doi.org/10.1182/blood-2010-01-266007

Published: 2010

Journal Articles

Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia

Blood (2009) 114 (1): 148–152.

https://doi.org/10.1182/blood-2008-11-187724

Published: 2009

Journal Articles

Differentiation syndrome in patients with acute promyelocytic leukemia treated with all- trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors

Blood (2009) 113 (4): 775–783.

https://doi.org/10.1182/blood-2008-07-168617

Published: 2009

Journal Articles

A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma

Laura Rosiñol, José Antonio Pérez-Simón, Anna Sureda, Javier de la Rubia, Felipe de Arriba, Juan José Lahuerta, José David González, Joaquín Díaz-Mediavilla, Belén Hernández, Javier García-Frade, Dolores Carrera, Angel León, Miguel Hernández, Pascual Fernández Abellán, Juan Miguel Bergua, Jesús San Miguel, Joan Bladé

Blood (2008) 112 (9): 3591–3593.

https://doi.org/10.1182/blood-2008-02-141598

Published: 2008

NARROW

Updated Results from the Phase 2 Waveline-004 Study of Zilovertamab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Epidemiology, Clinical Features and Outcomes of Peripheral T-Cell Lymphoma in Latin America

Quantitative Ki-67 Proliferative Index Assessment of Human B-Cell Lymphomas By Flow Cytometry

Zilovertamab Vedotin (MK-2140) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from the Phase 2 Waveline-004 Study

Primary CNS Lymphoma in Latin America: A Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL) Survey in 80 Cancer Centers in Latin America

Increased Frequency of Low-Grade Follicular Lymphoma with a High Proliferative Index: A First Step Towards Histological Transformation? a Retrospective Analysis of 25 Follicular Lymphoma Cases

Real-World Experience of Venetoclax Combination Therapy in Patients with Acute Myeloid Leukemia (AML): A Single-Institution Retrospective Study in a Middle-Income Country

Kinetics of Response to Bortezomib/Thalidomide/Dexamethasone (VTD) in Multiple Myeloma: Implications for the Choice and Design of Pretransplantation Induction Regimens

Tumor and Renal Response in Patients with Newly Diagnosed Multiple Mieloma and Renal Failure Treated with Bortezomib and Dexamethasone: Results of a Prospective Phase II Trial from Pethema/GEM

Observational Prospective Registry for the Assessment of the Clinical Impact of Starting Anti-Myeloma Treatment at Biological Relapse

Persistent Benefit of VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Long-Term Follow-up of a Randomized Phase 3 Pethema/GEM Study

Intensive (2+5) Or Semi-Intensive (FLUGA) Chemotherapy For Patients With Acute Myeloid Leukemia Who Are 70 Years Of Age Or Older

Minimal Residual Diease Evaluation By Flow Cytometry Is a Complementary Tool To Cytogenetics For Treatment Decision In Acute Myeloid Leukemia

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance

Risk-adapted treatment of acute promyelocytic leukemia based on all- trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome

Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia

Differentiation syndrome in patients with acute promyelocytic leukemia treated with all- trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors

A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only